Diagnostic and prognostic role of TFF3, Romo-1, NF-кB and SFRP4 as biomarkers for endometrial and ovarian cancers: a prospective observational translational study.
Biomarkers
Endometrial cancer
NF-кB
Ovarian cancer
Romo-1
SFRP4
TFF-3
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
02
03
2022
accepted:
01
04
2022
pubmed:
25
4
2022
medline:
8
11
2022
entrez:
24
4
2022
Statut:
ppublish
Résumé
This study aimed to evaluate trefoil factor 3 (TFF3), secreted frizzled-related protein 4 (sFRP4), reactive oxygen species modulator 1 (Romo1) and nuclear factor kappa B (NF-κB) as diagnostic and prognostic markers of endometrial cancer (EC) and ovarian cancer (OC). Thirty-one patients with EC and 30 patients with OC undergone surgical treatment were enrolled together with 30 healthy controls in a prospective study. Commercial ELISA kits determined serum TFF-3, Romo-1, NF-кB and sFRP-4 concentrations. Serum TFF-3, Romo-1 and NF-кB levels were significantly higher in patients with EC and OC than those without cancer. Regarding EC, none of the serum biomarkers differs significantly between endometrial and non-endometrioid endometrial carcinomas. Mean serum TFF-3 and NF-кB levels were significantly higher in advanced stages. Increased serum levels of TFF-3 and NF-кB were found in those with a higher grade of the disease. Regarding OC, none of the serum biomarkers differed significantly among histological subtypes. Significantly increased serum levels of NF-кB were observed in patients with advanced-stage OC than those with stage I and II diseases. No difference in serum biomarker levels was found between those who had a recurrence and those who had not. The sensibility and specificity of these four biomarkers in discriminating EC and OC from the control group showed encouraging values, although no one reached 70%. TFF-3, Romo-1, NF-кB and SFRP4 could represent new diagnostic and prognostic markers for OC and EC. Further studies are needed to validate our results.
Identifiants
pubmed: 35461390
doi: 10.1007/s00404-022-06563-8
pii: 10.1007/s00404-022-06563-8
pmc: PMC9633503
doi:
Substances chimiques
NF-kappa B
0
Biomarkers
0
TFF3 protein, human
0
Trefoil Factor-3
0
SFRP4 protein, human
0
Proto-Oncogene Proteins
0
ROMO1 protein, human
0
Membrane Proteins
0
Mitochondrial Proteins
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2105-2114Informations de copyright
© 2022. The Author(s).
Références
Cell Mol Life Sci. 2005 Dec;62(24):2956-73
pubmed: 16374584
Expert Rev Proteomics. 2019 Feb;16(2):93-103
pubmed: 30556752
Gland Surg. 2020 Aug;9(4):1102-1111
pubmed: 32953625
Chonnam Med J. 2019 Sep;55(3):136-143
pubmed: 31598470
PLoS One. 2012;7(2):e31885
pubmed: 22363760
Menopause. 2021 Nov 01;29(1):63-72
pubmed: 34726192
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Climacteric. 2020 Aug;23(4):355-359
pubmed: 32410475
Oncotarget. 2017 Aug 24;8(44):77268-77291
pubmed: 29100386
Virchows Arch. 2005 May;446(5):475-82
pubmed: 15856292
Crit Rev Oncog. 2019;24(1):99-104
pubmed: 31679224
J Minim Invasive Gynecol. 2020 Sep - Oct;27(6):1414-1416
pubmed: 31884079
Minim Invasive Ther Allied Technol. 2021 Jun;30(3):125-132
pubmed: 31971476
Int J Gynaecol Obstet. 2021 Dec;155(3):425-432
pubmed: 33686708
Tumour Biol. 2015 Jan;36(1):143-52
pubmed: 25501511
Pathol Oncol Res. 2018 Apr;24(2):277-282
pubmed: 28470574
Am J Pathol. 2002 May;160(5):1745-54
pubmed: 12000726
Transl Cancer Res. 2020 Dec;9(12):7725-7733
pubmed: 35117375
Endocr Relat Cancer. 2015 Jun;22(3):465-79
pubmed: 25900183
Clin Chim Acta. 2015 Oct 23;450:127-34
pubmed: 26265233
Adv Exp Med Biol. 2020;1219:355-363
pubmed: 32130708
Curr Pharm Des. 2018;24(40):4771-4778
pubmed: 30767733
Mol Cancer Res. 2008 Jun;6(6):1017-28
pubmed: 18567805
Br J Cancer. 2008 Sep 2;99(5):768-73
pubmed: 18682706
J Biol Chem. 2005 Mar 18;280(11):10564-71
pubmed: 15653692
Gastroenterology. 2012 Oct;143(4):1084-94.e7
pubmed: 22749933
Clin Cancer Res. 2002 May;8(5):1092-9
pubmed: 12006524
Ceska Gynekol. 2018 Summer;83(2):109-114
pubmed: 29869508
Prostate. 2004 Nov 1;61(3):215-27
pubmed: 15368473
Mol Clin Oncol. 2016 Oct;5(4):422-428
pubmed: 27699037
Eur J Cancer Prev. 2020 Jul;29(4):350-356
pubmed: 32516171
Minerva Med. 2020 Apr;111(2):133-140
pubmed: 32338842
Int J Oncol. 2015 May;46(5):2021-8
pubmed: 25673177
Clin Chem Lab Med. 2011 May;49(5):861-8
pubmed: 21275809
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:37-50
pubmed: 30306580
Cancer Biomark. 2013;13(4):201-13
pubmed: 24240581
Gynecol Oncol. 2019 Jul;154(1):163-168
pubmed: 31104904
Cancer Metastasis Rev. 2018 Mar;37(1):125-145
pubmed: 29392535
Eur J Gynaecol Oncol. 2009;30(2):133-41
pubmed: 19480240
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:59-78
pubmed: 30306591
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
J Pathol. 2004 Sep;204(1):19-27
pubmed: 15307134
Peptides. 2004 May;25(5):885-98
pubmed: 15177885
PLoS Med. 2020 Oct 28;17(10):e1003295
pubmed: 33112854
Expert Opin Investig Drugs. 2021 May;30(5):543-554
pubmed: 33724122
J Reprod Med. 2005 Aug;50(8):585-90
pubmed: 16220763
Clin Chim Acta. 2021 Apr;515:27-36
pubmed: 33388311
Cancers (Basel). 2020 Aug 20;12(9):
pubmed: 32825500
BMC Bioinformatics. 2012 Aug 17;13:206
pubmed: 22901030
Expert Rev Mol Diagn. 2017 Jun;17(6):577-591
pubmed: 28468520
Gynecol Oncol. 2013 Jul;130(1):174-80
pubmed: 23578537